Is Enasidenib covered by medical insurance in China?

Enasidenib (Enasidenib) The original drug is not currently on the market in China, so it cannot be included in medical insurance. If ensidipine can be marketed in the country, it is also expected to be reimbursed by medical insurance. Ensidipine is an anticancer drug. It is a ketone dehydrogenase inhibitor and is used to treat certain types of acute myeloid leukemia (AML). The drug can block the growth and development of leukemia cells by inhibiting ketone dehydrogenase, thereby reducing the progression of leukemia.

A phase II study of ensidipine showed an overall response rate of 40.3%, including a complete response rate of 19.3% and an incomplete count recovery rate of 6.8%. The median overall survival was 9.3 months, and those in complete response were 19.7 months. Based on the results of this phase II trial, IDH2 inhibitors provide an additional treatment option for patients with IDH2-mutated relapsed/refractory acute myeloid leukemia. The drug was generally well tolerated and the maximum tolerated dose was not reached. The most common treatment-related adverse events were hyperbilirubinemia and nausea. An important emergent adverse event was IDH inhibitor-associated differentiation syndrome, although no patients died from this in the study. You should follow your doctor's instructions when using this drug and use it strictly as prescribed.

The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad.